Novo Nordisk's Oral Wegovy Bets on German Pharmacy Shelves to Reset a Bruised Narrative

Novo Nordisk rolls out oral Wegovy in Germany, first EU market, as investors await strategy update on Sept 21 amid mixed analyst views.

The tablet is smaller than the injection pen it aims to complement, but the strategic weight Novo Nordisk is loading onto it could hardly be heavier. Germany became the first EU market this week to stock the oral version of Wegovy, priced between €170 and €280 depending on dosage — a deliberate echo of the existing pen pricing that belies how much the company is counting on the format shift to change its trajectory.

The launch lands barely a fortnight before the Danish drugmaker's Capital Markets Day in London on 21 September, where management is expected to lay out its multi-year strategy. That timing turns a routine product rollout into something more consequential: a first tangible signal that Novo Nordisk can still execute operationally before it has to sell investors on the bigger picture.

Investors have already marked the shares up from the depths of March, when they touched a 52-week low of €30.25. At roughly €40.50, the stock sits about a quarter below its January high of €54.86 — a wide band that captures a company neither written off nor restored to former glory.

A Pill Designed to Reopen a Pipeline of Prescriptions

The core question hanging over the oral launch is straightforward: can it revive prescription momentum that has visibly cooled for the injectable franchise? Citi, which reaffirmed its sell rating on 2 September, pointed to GLP-1 prescription trends that have gone soft — total Ozempic scripts down 9 percent on a rolling four-week basis, with new prescriptions off 3 percent.

The tablet's logic is that it removes the needle barrier entirely, potentially reaching patients who have steered clear of injections. Whether that translates into scripts quickly enough to offset the Ozempic slide is the metric that will define the coming weeks.

There are counterweights to the bearish case. In November, Novo Nordisk agreed to reduce semaglutide prices in the US across Medicare, Medicaid and a direct-to-consumer channel, with NovoLog and Tresiba offered at $35 per month through the TrumpRx programme. Broader access to cheaper products could steady US prescription numbers and blunt the weakness Citi flagged.

Two Banks, Two Readings of the Same Company

The analyst community is unusually split on this name. Deutsche Bank cut its rating to sell on 27 August, trimming its price target from DKK 290 to DKK 265, citing slower expected growth in 2027, the failure of late-stage candidate Ziltivekimab in cardiovascular disease, and looming patent expiries. JPMorgan, by contrast, lifted its target to DKK 275 in early August while keeping a neutral stance, arguing that generic erosion of Ozempic would prove milder than feared.

Two respected houses reached nearly opposite conclusions within weeks of each other — a reminder of how genuinely uncertain the outlook is, even among those who follow the company full-time.

The second-quarter numbers do little to settle the debate. Adjusted revenues rose 7 percent on a currency-adjusted basis, with adjusted operating profit up 11 percent. Management responded by lifting full-year guidance from a range of minus 4 to minus 12 percent to between 0 and minus 6 percent for both revenue and operating profit on a CER basis. An improvement, certainly, but still a forecast carrying a minus sign — growth, but not the kind Novo Nordisk shareholders grew accustomed to in better years.

Capital Returns That Mask a Structural Problem

The company has returned DKK 41.2 billion to shareholders in the first half through dividends and buybacks. Its current DKK 15 billion repurchase programme, running since early February, had accumulated roughly 31 million B-shares at an average price of DKK 281.08 by the end of August. Yet the share price has barely moved since the programme began — the market accepts the capital discipline while recognising it does nothing to address intensifying competition from Eli Lilly.

That is the tension at the heart of the current story: operational progress and generous capital returns on one side, eroding market share and competitive pressure on the other.

A Second Front Opening in the East

Beyond Germany, the company is also pressing forward in China, where the drug regulator accepted the oral Wegovy application just over a week ago. The potential demand there is enormous, though regulatory timelines remain notoriously unpredictable — Novo Nordisk is offering no guidance on approval dates, a silence typical of an industry where patience is a core competency.

What to Watch Before London

Until prescription data for the oral products shows a clear inflection, the stock looks likely to remain rangebound. The technical picture reinforces that view: the shares sit a mere 0.8 percent above their 200-day moving average, suggesting no decisive directional conviction from the market.

If German prescription numbers build steadily in the coming weeks, the Capital Markets Day could become a catalyst for a more constructive reassessment. If they falter, the event risks being read as confirmation of the sceptics' view rather than a turning point. Either way, the pill on German pharmacy shelves is now the most tangible expression of how Novo Nordisk hopes to recombine its traditional strengths — market access, pricing power, global reach — to compete in the fiercest fight of its corporate life.